Related Experiment Video
Updated: Aug 7, 2025

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer's Disease
Ivana Raffaele1, Serena Silvestro1, Emanuela Mazzon1
1IRCCS Centro Neurolesi Bonino Pulejo, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.
Abstract:
Alzheimer's disease (AD) is a neurodegenerative disorder known to be the leading cause of dementia worldwide. Many microRNAs (miRNAs) were found deregulated in the brain or blood of AD patients, suggesting a possible key role in different stages of neurodegeneration. In particular, mitogen-activated protein kinases (MAPK) signaling can be impaired by miRNA dysregulation during AD. Indeed, the aberrant MAPK pathway may facilitate the development of amyloid-beta (Aβ) and Tau pathology, oxidative stress, neuroinflammation, and brain cell death. The aim of this review was to describe the molecular interactions between miRNAs and MAPKs during AD pathogenesis by selecting evidence from experimental AD models. Publications ranging from 2010 to 2023 were considered, based on PubMed and Web of Science databases. According to obtained data, several miRNA deregulations may regulate MAPK signaling in different stages of AD and conversely. Moreover, overexpressing or silencing miRNAs involved in MAPK regulation was seen to improve cognitive deficits in AD animal models. In particular, miR-132 is of particular interest due to its neuroprotective functions by inhibiting Aβ and Tau depositions, as well as oxidative stress, through ERK/MAPK1 signaling modulation. However, further investigations are required to confirm and implement these promising results.
Insights
MicroRNAs (miRNAs) are implicated in Alzheimer's disease (AD) by affecting mitogen-activated protein kinases (MAPK) signaling. Targeting specific miRNAs, like miR-132, shows potential for treating AD by reducing pathology and improving cognition.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is the primary cause of dementia globally, characterized by neurodegeneration.
- Dysregulated microRNAs (miRNAs) are observed in AD patients, suggesting their involvement in disease progression.
- Mitogen-activated protein kinases (MAPK) signaling pathways are crucial in cellular functions and can be disrupted in AD.
Purpose of the Study:
- To review the molecular interplay between miRNAs and MAPKs in Alzheimer's disease pathogenesis.
- To consolidate evidence from experimental AD models regarding miRNA-MAPK interactions.
- To identify specific miRNAs with therapeutic potential in AD.
Main Methods:
- Systematic literature review of publications from 2010-2023.
- Searches conducted on PubMed and Web of Science databases.
- Focus on experimental models of Alzheimer's disease.
Main Results:
- Multiple miRNA deregulations were found to modulate MAPK signaling in various stages of AD.
- Modulation of MAPK-regulating miRNAs (overexpression or silencing) ameliorated cognitive deficits in AD animal models.
- miR-132 demonstrated neuroprotective effects by inhibiting amyloid-beta and Tau pathology and oxidative stress via ERK/MAPK1 signaling.
Conclusions:
- miRNAs play a significant role in regulating MAPK signaling during AD pathogenesis.
- miRNA-based interventions show promise for improving cognitive function in AD models.
- Further research is needed to validate and translate these findings into clinical applications for Alzheimer's disease.
More Related Videos
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
07:55Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
Related Concept Videos
MicroRNAs
Microtubule Associated Proteins (MAPs)
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Microtubule Instability